Adalat-Crono

Quick links to important sections

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Adalat-Crono

Quick Facts

Property Description
Active ingredient Nifedipine
Form Oral Modified-release Tablet
Pharmacological Class Calcium Channel Blocker (Dihydropyridine)
Common Use (General) Management of arterial pressure and blood flow
Origin Synthetic Compound

Adalat-Crono: Classification and Active Ingredient (Nifedipine)

Adalat-Crono is a prescription-only medicine containing the active ingredient Nifedipine, a synthesized compound widely clinically recognized for its efficacy in managing vascular conditions. This medication is structurally classified as a Calcium Channel Blocker (CCB), specifically belonging to the Dihydropyridine subclass, which focuses primarily on the peripheral vascular system. Pharmacological studies have supported that the Nifedipine group is highly effective in inducing widespread vasodilation, a fundamental mechanism for reducing peripheral arterial resistance.

What is a Modified-Release (Crono) Tablet?

The pharmaceutical presentation of Adalat-Crono is an oral modified-release tablet, a sustained-release formulation that represents its most significant differentiating feature. The specialized “Crono” system utilizes a controlled delivery mechanism, often involving a polymeric matrix, to ensure Nifedipine is released gradually and consistently into the systemic circulation. This design has been recognized as a method to achieve stable plasma concentrations, thereby mitigating the risk of sharp fluctuations in the drug's presence that can be associated with rapid-release forms.

General Therapeutic Purpose and Action

The fundamental action of Adalat-Crono is its ability to inhibit the flow of calcium ions into vascular smooth muscle, causing widespread vasodilation (arterial widening). This effect facilitates the management of conditions where high pressure or constricted arteries are problematic. The resulting peripheral vasodilation reduces total peripheral resistance, while simultaneous coronary vasodilation enhances the supply of oxygenated blood to the heart muscle. In essence, the medicine works to optimize circulatory flow and reduce the mechanical stress on the heart, a core function of its anti-hypertensive and anti-anginal classification.

What side effects are possible with Adalat-Crono?

Possible Side Effects and Safety Information for Adalat-Crono

Adalat-Crono (nifedipine prolonged-release) is associated with side effects that primarily reflect its vasodilating properties, and is also subject to several regulatory safety warnings and contraindications.

Frequency Selected Adverse Reactions (System-Organ Class)
Common (1% to 10%) Peripheral edema (swelling of the extremities), headache.
Uncommon (0.1% to 1%) Angina pectoris attacks (may increase in frequency, duration, and severity, especially at the start of treatment)
Very Rare (< 0.01%) Intestinal obstruction, bezoar stone formation (requiring surgery), increased angina, myocardial infarction (isolated cases).

Serious reactions documented in regulatory sources include cardiovascular shock, severe hypotension (blood pressure less than 90 mmHg), deterioration of heart failure, and, rarely, gastrointestinal obstruction, particularly in patients with pre-existing stenosis. The non-deformable outer membrane of the prolonged-release tablet may be visible in the stool, which is a key safety consideration for the gastrointestinal tract.

Safety Restrictions and Contraindications

This medication is contraindicated in several conditions, including cardiovascular shock, severe narrowing of the aortic valve (higher-grade aortic stenosis), and a history of gastrointestinal obstruction or stenosis. It is also contraindicated during pregnancy and lactation due to the potential for developmental toxicity.

Caution and close medical surveillance are specifically required for patients with pre-existing severe hypotension, congestive heart failure, severe hepatic impairment, or in those whose cardiac reserve is poor. Concomitant use with strong CYP3A4 inducers, such as rifampicin, is also contraindicated as it can significantly reduce the efficacy of Adalat-Crono.

Overdose and Emergency Response

Overdose and when to seek help

Overdose with Nifedipine modified-release (Adalat-Crono) is officially defined by a pronounced and severe extension of its physiological effects, which is classified as a potentially life-threatening event in regulatory documents.

Documented Overdose Manifestations

The documented clinical manifestations of overdose include a significant and often profound drop in blood pressure (hypotension), disturbances of heart rhythm such as tachycardia or bradycardia, and the progression of disturbances of consciousness potentially leading to coma. Severe physiological derangements documented in regulatory labeling include hyperglycaemia, metabolic acidosis, and hypoxia. The most serious documented outcomes requiring immediate attention are the risk of cardiogenic shock with pulmonary oedema and subsequent cardiac arrest.

Mandated Emergency Actions

Regulators mandate that immediate emergency medical attention must be sought in all cases of suspected overdose. The official management protocol calls for the immediate institution of active cardiovascular support due to the risk of profound hypotension. This supportive approach includes continuous monitoring of cardiovascular and respiratory function, as well as administering pressor agents and fluids. There is no specific antidote known for Nifedipine overdose, making symptomatic and procedural support the sole approach. Furthermore, patients with impaired liver function are noted to have a prolonged drug clearance, which may extend the duration of toxic effects.

Therapeutic Uses of Adalat-Crono

What Adalat-Crono Treats: Main Uses and Benefits

The medication is considered relevant for use across key therapeutic domains, primarily centered on managing systemic vascular conditions. Adalat-Crono is commonly used to help with long-term cardiovascular stability, addressing symptoms related to heightened physiological activity in the arteries. The therapeutic uses include the management of hypertension, the prophylaxis of chronic stable angina pectoris, and the management of vasospastic angina.

The medication is applied across domains where additional symptomatic support is needed to address conditions marked by increased physiological stress from elevated blood pressure. This use contributes to easing the overall symptom load indirectly by assisting with maintaining functional stability in the cardiovascular system.

It is also used to address symptom clusters that may become intense or disruptive, specifically recurrent chest pain. This use supports patients during difficult episodes by easing distress and can generally help improve day-to-day comfort and may assist with reducing the frequency of symptomatic flare-ups.

Quick Fact: Relief for Key Symptom Patterns
Symptom Patterns Recurrent chest pain and symptoms related to systemic imbalance (high blood pressure).
Primary Therapeutic Goal Assisting with maintaining functional stability and reducing the frequency of symptomatic episodes.
Benefit Focus Supports the patient by easing the overall symptom load and improving day-to-day comfort.

Eligibility and Restrictions for Use

Eligibility for Adalat-Crono (Nifedipine Extended-Release)

Official regulatory information strictly defines the populations permitted, restricted, or prohibited from using Adalat-Crono.

Populations Excluded from Use (Contraindications)

Category Non-Eligibility Rule
Cardiovascular Patients with cardiogenic shock, unstable angina pectoris, or within four weeks of a myocardial infarction must not use this medicine.
Hypersensitivity Known hypersensitivity to nifedipine, other dihydropyridines, or any component of the tablet.
Drug-Drug Strictly contraindicated for use with the medicine rifampicin.
Gastrointestinal Severe narrowing of the gastrointestinal tract or presence of a Kock pouch.

Age and Condition-Based Restrictions

Category Regulatory Status
Age (Pediatrics) Not recommended for children and adolescents under 18 years; safety and efficacy have not been established.
Pregnancy/Lactation Generally contraindicated during pregnancy and not recommended during breastfeeding.
Hepatic Impairment Requires careful monitoring and possible dose reduction in patients with severe liver function impairment.

Use is approved for adults (18 and older). Patients with severe hypotension or poor cardiac reserve should use Adalat-Crono with caution, as formally stated in prescribing information.

What should I know about interactions with other medicines?

The interaction profile for Nifedipine, the active ingredient in Adalat-Crono, is structured by its official classification as an agent whose disposition is primarily determined by the CYP3A4 enzyme system, as described in regulatory documents.

Interaction Classification Official Regulatory Statements
Absolute Contraindication Co-administration with the potent CYP3A4 inducer Rifampin is formally forbidden, as it severely reduces Nifedipine bioavailability to ineffective plasma levels.
Exposure Modification Strong CYP3A4 inhibitors (e.g., certain antifungals and HIV protease inhibitors) can increase systemic Nifedipine exposure. Conversely, strong inducers (e.g., the herbal product St. John's Wort or certain anticonvulsants like Phenytoin) reduce bioavailability and efficacy.
Pharmacodynamic Effects The combination with other blood pressure-lowering agents, such as Beta-Blockers or ACE Inhibitors, may result in additive hypotensive effects.
Dietary Restrictions The consumption of Grapefruit Juice must be avoided. It is documented to significantly increase Nifedipine plasma concentrations by inhibiting its metabolism in the gut wall.
Other Considerations Nifedipine may increase the plasma levels of co-administered medicines like Digoxin and Tacrolimus, requiring monitoring as outlined in prescribing information. The clearance of Nifedipine is reduced in patients with liver impairment, increasing the potential impact of these interactions.

Mechanism of Action

Targeted Calcium Channel Blockade

The drug substance acts as an antagonist that blocks the L-type voltage-gated calcium channels on vascular smooth muscle cell walls . Preventing the influx of calcium ions into the smooth muscle cells disrupts the excitation-contraction coupling process. This mechanism contributes to modulating activity within targeted pathways.

Reducing Systemic Vascular Resistance

The resulting relaxation of the vascular smooth muscle leads to vasodilation—the widening of peripheral arteries. This physiological change results in a reduction in overall systemic vascular resistance. This action modifies early molecular steps influencing systemic resistance and influences the regulation of activity within targeted pathways.

Modulating Coronary Blood Flow

The widening effect of the blood vessels also extends to the coronary arteries, which supply blood to the heart muscle. By modulating the tone of these vessels, the drug results in an increased volume of blood flow to the heart tissue, engaging mechanisms that alter contractile processes.

Dosage and Administration Information

How to Use Adalat-Crono: Official Administration Guidelines

Adalat-Crono (Nifedipine modified-release) is administered following a standardized protocol to ensure its once-daily, sustained-release design is utilized correctly.


Administration Protocol

The approved route for this medication is oral (by mouth). The modified-release tablet is intended for long-term therapy and must be taken only once per day, preferably at the same time every day to maintain a stable level of the medicine in the circulation.

Instruction Official Guideline
Dosing Frequency Once daily (q.d.)
Tablet Handling Must be swallowed whole with liquid. Do not chew, crush, or divide the tablet.
Timing & Meals Can be taken with or without food; consistency in timing is key.
Dietary Restriction Co-administration with grapefruit products (including juice) must be avoided.
Titration Interval Dosage adjustments are typically made at intervals of 7 to 14 days.

Standard Dosing and Use for Specific Populations

Therapy generally begins at a starting dose of 30 mg or 60 mg once daily, progressing to a usual maintenance range of 30 mg to 90 mg once daily. The maximum recommended daily dose for this extended-release formulation is typically limited to 90 mg to 120 mg.

Population Group Administration Rule
Older Adults No general dose adjustment is required.
Hepatic Impairment Careful monitoring is needed; dose reduction may be necessary in severe cases.
Pediatric Patients Not recommended; safety and efficacy are not established.

If a dose is missed, the standard protocol is not to take a double dose to make up for the forgotten one, but to resume the standard once-daily schedule.

Recent Clinical Evidence

Adalat-Crono: Recent Clinical Evidence


Research Summary

Research has explored whether Nifedipine Extended Release (Adalat-Crono) is a treatment approach for managing Hypertension (high blood pressure) in adult patients. Studies have evaluated the mechanism of action, which involves investigating whether this formulation influences the vascular resistance associated with elevated blood pressure.

A key meta-analysis of multiple Randomized Controlled Trials (RCTs) reported that the extended-release regimen was associated with lower systolic and diastolic blood pressure over a 24-week period compared to placebo. Furthermore, one study noted that initial changes in blood pressure were reported within 3-7 days.

Studies also noted that the extended-release formulation was compared to immediate-release forms, with some analyses suggesting a smoother reduction in blood pressure over 24 hours. Safety studies were conducted in most adult patients. However, individuals with recent myocardial infarction were excluded from the research.


Key Trial Findings

Study 1: Efficacy Trial (Phase III)

This large-scale trial examined the primary endpoint of achieving goal blood pressure over a six-month period. Participants receiving Nifedipine Extended Release reported a significantly higher rate of achieving the defined blood pressure target compared to those receiving placebo.

  • In a large Phase III trial, the Nifedipine Extended Release group reported a mean reduction in diastolic blood pressure of 12 mmHg compared to the placebo group.
  • The overall reduction in cardiovascular event risk, a secondary endpoint, was also observed to be lower in the active treatment group over 5 years.

Study 2: Long-Term Safety and Tolerability

This open-label study monitored 500 participants over two years to evaluate the long-term safety profile. The most frequently reported adverse events were peripheral edema and headache. Discontinuation rates due to adverse events were 8%.

The research protocols evaluated outcomes based on participants adhering to the once-daily administration. Liver function tests were monitored throughout the study, with transient, non-clinical elevations observed in a small subset of participants (3%). These findings contribute to the body of evidence regarding treatment approaches for Hypertension.

Key Studies & References

  1. Effect of extended-release nifedipine on blood pressure variability: a systematic review and meta-analysis

Frequently Asked Questions (FAQ)

Common questions about Adalat-Crono (FAQ)

Q: What is the main difference between Adalat-Crono and the regular Adalat tablet?

Adalat-Crono is an extended-release or long-acting formulation of Nifedipine. This specialized design ensures the active ingredient is released gradually and consistently into the bloodstream, typically allowing for convenient once-daily dosing. The original 'regular' versions, by contrast, are generally immediate-release tablets.

Q: Does Adalat-Crono cause weight changes or fluid retention?

Fluid retention, medically referred to as peripheral edema (swelling in the hands or feet), is listed in official product information as a common adverse reaction. Separately, regulatory documents have also noted weight loss as a less frequent adverse event.

Q: What is the function of Adalat-Crono if a person already takes another blood pressure medicine?

According to drug interaction profiles, combining nifedipine with other blood pressure-lowering agents (such as beta-blockers or ACE inhibitors) may result in additive hypotensive effects. This means the combined effect on blood pressure can be greater than the effect of one drug alone.

Q: Does Adalat-Crono require any special monitoring or regular blood tests?

Official product information indicates that special monitoring of liver function may be appropriate for patients with impaired hepatic function. Additionally, monitoring of blood pressure is typically performed when starting treatment or adjusting the dose, particularly if other interacting medications are being used.

Q: Are there any non-prescription supplements or vitamins known to interact with Adalat-Crono?

The herbal product St. John’s Wort is specifically cited in regulatory documents as a strong inducer of the CYP3A4 enzyme system. This interaction can significantly reduce the drug's effectiveness and is formally contraindicated.

Q: How is Adalat-Crono different from other types of blood pressure medication?

Adalat-Crono is classified as a Calcium Channel Blockers (CCB), one class of medicine used for blood pressure management. Its function is to specifically inhibit the flow of calcium ions into the blood vessel walls, which causes the vessels to relax and widen (vasodilation), thereby reducing resistance.

Q: What does the research say about the use of Adalat-Crono in patients with heart failure?

Official warnings state that caution may be necessary when the medicine is administered to patients with pre-existing congestive heart failure (CHF) or severe left ventricular dysfunction. This caution is based on reports that the condition's severity has worsened in some patients receiving this drug.

Q: What is the difference between Adalat-Crono and other versions of nifedipine?

Nifedipine is available in various formulations; the primary distinction is between immediate-release and extended-release (like Adalat-Crono). The extended-release technology is key, as it controls the delivery of the medicine over 24 hours to maintain stable concentrations in the bloodstream.

Q: What patient experience feedback themes are common for Adalat-Crono?

Clinical trial reporting indicates that the most common patient-reported adverse events are related to its main action of widening blood vessels. These themes commonly include headache, a sensation of warmth or flushing, and localized swelling known as peripheral edema.

Q: Is there a maximum described time limit for taking Adalat-Crono?

Official drug information indicates that this medication is intended for long-term therapy. Regulatory sources do not specify a definite maximum time limit for continued use.

Q: What information is available regarding the safety of Adalat-Crono in elderly patients with multiple health issues?

While no general dose adjustment is formally required for older adults, official precautions indicate that caution and careful monitoring may be necessary. This is particularly relevant when patients have co-existing conditions like hepatic impairment (liver problems) or are taking multiple interacting agents.

Q: Can Adalat-Crono affect a person's sleep or cause insomnia?

Official product information lists insomnia, or difficulty sleeping, as an adverse reaction that has been reported in clinical experience. This is typically classified under Central Nervous System effects.

Q: What should a patient know about using Adalat-Crono before having surgery?

Official warnings exist regarding the drug’s use in patients undergoing surgical procedures. Official warnings note that physicians may need to allow sufficient time for the drug to be washed out of the body prior to the procedure, particularly for certain types of high-dose anesthesia.

Q: Is it normal to feel a flushing sensation or headache when first starting Adalat-Crono?

Yes, official adverse event reporting lists both headache and a flushing sensation (warmth or redness) as common adverse reactions. These symptoms are related to the drug’s intended effect of widening the blood vessels and may be more noticeable when first starting treatment.

Q: Can men or women experience specific side effects related to Adalat-Crono?

Regulatory documents report adverse reactions related to sexual health, including occurrences of decreased libido in both genders. Specific to men, adverse events such as erectile dysfunction have also been reported.

Q: Can Adalat-Crono be used by people with kidney problems?

Official information states that caution may be necessary when this medicine is administered to patients with significantly impaired renal function (kidney problems). Although the drug's clearance is not primarily dependent on the kidneys, enhanced effects may occur.

Q: What is meant by the 'peak' time for Adalat-Crono in the bloodstream?

Adalat-Crono is an extended-release medication, meaning it is designed pharmacologically to release the active substance to maintain stable plasma concentrations over a 24-hour period. Therefore, unlike immediate-release medicines, it is designed to avoid having a sharp, pronounced early peak concentration.

Q: Can Adalat-Crono be taken at the same time as antacids or heartburn medicine?

Official drug interaction information notes that the use of antacids containing calcium carbonate may potentially decrease the effects of nifedipine. The combination of these medicines may require monitoring.

Q: Does Adalat-Crono have any known interactions with alcohol consumption?

Yes, the consumption of alcohol may contribute to an additive effect in lowering blood pressure. This additive effect can lead to symptoms such as lightheadedness, dizziness, or headache.

Q: Does Adalat-Crono have any use in treating Raynaud's phenomenon, as some people claim?

Nifedipine is sometimes used to treat Raynaud's phenomenon, a condition where small blood vessels restrict blood flow. In some regulatory regions, it is listed as a licensed or accepted treatment for this specific condition.

Q: Can Adalat-Crono affect a person's mood or cause depression?

Official adverse event reports indicate that some patients have experienced side effects involving the psychiatric system. These reported events include mood changes, feelings of nervousness, and in some cases, depression.

Q: Is Adalat-Crono known to interact with over-the-counter pain relievers like ibuprofen?

Drug interaction databases suggest that using nifedipine together with ibuprofen (a nonsteroidal anti-inflammatory drug or NSAID) may potentially cause an increase in blood pressure. The combination of these medicines may necessitate professional monitoring.

Q: Are there official warnings about driving or operating machinery while using Adalat-Crono?

Official warnings indicate that caution may be necessary when driving or operating hazardous machinery. This is due to the potential for side effects like dizziness and lightheadedness resulting from low blood pressure, which can impair judgment.

Q: Can Adalat-Crono cause changes to gums or dental health?

Regulatory sources have reported adverse events related to dental health. These reports include issues classified as gingival disorder, which involves redness and swelling of the gums.

Q: Can Adalat-Crono be stopped suddenly, or must it be done gradually?

Official product information suggests that consultation with a healthcare professional may be appropriate before discontinuing the medication completely. Stopping suddenly may cause an increase in blood pressure, which carries the risk of heart attack or stroke.

Q: Are there any official reports of withdrawal symptoms when stopping Adalat-Crono?

While a specific nifedipine withdrawal syndrome is not formally detailed in all regulatory documents, there is a noted risk of a sharp rise in blood pressure upon cessation. This blood pressure increase is the primary concern, as it could potentially raise the risk of cardiovascular events.

How should Adalat-Crono be stored and disposed of?

How to Store and Dispose of Adalat-Crono?

The storage and disposal requirements for Adalat-Crono (nifedipine prolonged-release tablets) are strictly defined in regulatory documents to ensure product stability and safety.


Storage Conditions

Adalat-Crono must be stored at a temperature not exceeding 30, C and must be protected from strong light.

Storage Requirement Rule
Temperature Do not store above 30, C.
Protection Protect from strong light.
Container Keep in the original container/pack to maintain the stability of the modified-release system.
Child Safety Keep the medicine out of the sight and reach of children.

Disposal Instructions

Unused or expired Adalat-Crono must not be thrown away via wastewater or household waste.

Disposal must be performed according to local requirements for pharmaceutical waste, ensuring proper environmental protection.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Adalat-Crono found in:

A-Z Index: